Coya Therapeutics Inc COYA.OQ COYA.O is expected to show a rise in quarterly revenue when it reports results on November 4 (estimated) for the period ending September 30 2025
The Houston Texas-based company is expected to report revenue of $3.7 million, according to the mean estimate from 7 analysts, based on LSEG data.
LSEG's mean analyst estimate for Coya Therapeutics Inc is for a loss of 28 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Coya Therapeutics Inc is $15.50, about 60.5% above its last closing price of $6.12
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -0.45 | -0.39 | -0.36 | Beat | 8.4 |
Mar. 31 2025 | -0.17 | -0.19 | -0.44 | Missed | -125.6 |
Dec. 31 2024 | -0.24 | -0.26 | -0.17 | Beat | 35.8 |
Sep. 30 2024 | -0.41 | -0.41 | -0.26 | Beat | 37.3 |
Jun. 30 2024 | -0.14 | -0.14 | -0.19 | Missed | -35.7 |
Mar. 31 2024 | -0.30 | -0.30 | -0.35 | Missed | -16.7 |
Dec. 31 2023 | 0.26 | 0.26 | 0.28 | Beat | 7.7 |
Sep. 30 2023 | -0.37 | -0.37 | -0.48 | Missed | -29.7 |
This summary was machine generated October 31 at 13:55 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)